- Receipt of opioid substitution therapy (OST) is the greatest predictor of HCV screening among Danish individuals in treatment from drug use.
Why this matters
- The lag observed between IDU initiation and first HCV test suggests a need for upscaled screening outside OST settings.
- Registry-based study of 5483 individuals (median age, 23 years; 25% female) treated for drug use during 1996-2015.
- 50% reported IDU or OST; 32% of IDU reported injecting stimulants.
- Funding: Gilead Nordic Fellowship, University and Region of Southern Denmark.
- HCV test uptake was 51.9% overall, and higher among high-risk vs low-risk individuals (76.6% vs 31.1; P<.01>
- Median time from first IDU to HCV testing, 6.5 years.
- At end of follow-up, 21.2% of remaining individuals were HCV RNA+.
- In multivariate analysis, predictors of HCV testing included:
- Receiving OST (OR=3.7).
- Ever IDU (OR=2.3)
- Female gender (OR=1.7)
- Connection to hepatitis outreach centers (OR=1.4; P<.01 for all>
- Predictors of HCV included IDU (OR=6.7; P<.01 and history of ost p>
- 69% of 531 HCV+ individuals were in drug use treatment at end of follow-up.
- After 2010, only 4.7% of new participants reported opiates as the drug of choice and 17% reported IDU.
- Retrospective, observational design.